Clinical Research Directory

Inclusion Criteria: * 1\. Adult rheumatoid arthritis patients(≥18 years) who fulfilled the 1987 American College of Rheumatology (ACR) criteria or the 2010 ACR/European League Against Rheumatism (EULAR) criteria. * 2\. Had been taking 5-10 mg oral prednisolone (or equivalent) daily glucocorticoids for longer than 3 months at screening and were expected to receive glucocorticoids for at least another 12 months. * 3\. Ambulant outpatients * 4\. Written informed consent Exclusion Criteria: * 1\. BMD T\<-3.0 measured by DXA at screening * 2\. Vertebral, hip, proximal humerus, pelvis, or distal forearm fragility fracture history * 3\. Any severe bone disorder or deformation at the lumbar spine that would affect DXA measurement * 4\. Primary hyperparathyroidism, Cushing's syndrome, hyperthyroidism, gonadal insufficiency, osteogenesis impotence, poorly controlled diabetes mellitus (HbA1c\>9%), or other diseases that can affect bone metabolism * 5\. Had injected bisphosphonate once or more within 3 years before entering the study; or had received oral bisphosphonate for 6 months or more in the 3 years prior to study entry; or had received parathyroid hormone once or more in the 3 years before entering the study; or received 2 weeks or more of calcitonin or vitamin K or selective estrogen receptor modulator or hormone replacement therapy or traditional Chinese medicine for osteoporosis within 2 months prior to study entry; or received active vitamin D within 2 weeks prior to study entry; or received subcutaneous anti-RANKL antibody at any time prior to study entry * 6\. Urolithiasis at screening or had a history of urolithiasis * 7\. Hypercalcemia (serum calcium \>10.4 mg/dL), or hypercalciuria (fasting morning urine calcium/creatinine \>400 mg/gCr or 24h urine calcium \>300mg), or had serum creatinine levels above the reference range * 8\. Severe liver disease such as cirrhosis or serious heart disease such as severe heart failure * 9\. Active malignant tumors or a history of malignant tumors within 5 years before informed consent obtained * 10\. History of allergy to vitamin D * 11\. Pregnant women or female patients planning to become pregnant during the study * 12\. Other inappropriate situations judged by investigators